-
Product Insights
NewOpium (Opioid) Addiction – Drugs In Development, 2024
Empower your strategies with our Opium (Opioid) Addiction – Drugs In Development, 2024 report and make more profitable business decisions. Opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers, known as endorphins). This can lead to an inability of the body to stop pain, because there are no endorphins to mask the pain initially. The degeneration...
-
Product Insights
NewAlcohol Addiction – Drugs In Development, 2024
Empower your strategies with our Alcohol Dependence – Drugs In Development, 2024 report and make more profitable business decisions. Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking, and violent behavior. Risk factors include age, family history, and depression or other mental health problems. The Alcohol Dependence drugs in development market research report provide comprehensive information on the therapeutics under development for Alcohol Dependence, complete with...
-
Product Insights
NewNet Present Value Model: Aptinyx Inc’s Risevistinel
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewNet Present Value Model: Aptinyx Inc’s NYX-458
Empower your strategies with our Net Present Value Model: Aptinyx Inc's NYX-458 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Profile
Aptinyx Inc – Company Profile
Aptinyx Inc (Aptinyx) is a pharmaceutical and healthcare company. It is headquartered in Foxborough, Massachusetts, the US.
Add to Basket -
Product Insights
Net Present Value Model: NYX-458
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model NYX-458 Drug Details NYX-458 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NYX-458
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NYX-458 Drug Details NYX-458 is under development for the treatment of mild cognitive impairment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NYX-783
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NYX-783 Drug Details NYX-783 is under development for the treatment of post-traumatic stress disorder,...
-
Product Insights
Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Mild Cognitive Impairment pipeline market report provides a comprehensive overview of the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive...